The Vanderbilt University

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Ifetroban in Treating Patients With Malignant Solid Tumors at High Risk of Metastatic Recurrence

Phase 2

Active, not recruiting

Conditions: Malignant Solid Tumor

Interventions: Other: Placebo
Drug: Ifetroban Sodium

First Posted Date: 2018-10-03

Last Posted Date: 2024-06-27

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 30

Registration Number: NCT03694249

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

Afatinib and Nivolumab as Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Phase 1

Withdrawn

Conditions: Metastatic Squamous Cell Carcinoma of the Head or Neck
Squamous Cell Carcinoma
Recurrent Squamous Cell Carcinoma of the Head or Neck

Interventions: Drug: Nivolumab
Drug: Afatinib

First Posted Date: 2018-08-29

Last Posted Date: 2019-06-20

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Registration Number: NCT03652233

Tumor-Treating Fields Therapy in Preventing Brain Tumors in Participants With Extensive-Stage Small Cell Lung Cancer

Not Applicable

Terminated

Conditions: Extensive Stage Small Cell Lung Carcinoma

Interventions: Procedure: Tumor Treating Fields (TTF) Therapy
Device: NovoTTF-200A Device
Other: Quality-of-Life Assessment

First Posted Date: 2018-07-31

Last Posted Date: 2020-08-04

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 2

Registration Number: NCT03607682

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors

Phase 1

Completed

Conditions: Thymic Carcinoma
Non-small Cell Lung Cancer
Refractory Thoracic Tumors
Small-Cell Lung Cancer

Interventions: Drug: Vorolanib
Biological: Nivolumab

First Posted Date: 2018-07-11

Last Posted Date: 2024-10-08

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 88

Registration Number: NCT03583086

Locations: 🇺🇸
Baptist Clinical Research Institute, Memphis, Tennessee, United States
🇺🇸
Winship Cancer Institute, Emory University, Atlanta, Georgia, United States
🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States

and more 4 locations

Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer

Phase 1

Terminated

Conditions: Stage III Breast Cancer
HER2/Neu Negative
Stage IV Breast Cancer
Estrogen Receptor-positive
Stage IIIA Breast Cancer
Stage IIIB Breast Cancer
Stage IIIC Breast Cancer

Interventions: Drug: Atezolizumab
Drug: Cobimetinib
Drug: Idasanutlin

First Posted Date: 2018-06-25

Last Posted Date: 2021-08-11

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 12

Registration Number: NCT03566485

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

Rituximab, Lenalidomide, and Nivolumab in Treating Participants With Relapsed or Refractory Non-Germinal Center Type Diffuse Large B Cell Lymphoma or Primary Central Nervous System Lymphoma

Phase 1

Terminated

Conditions: Recurrent Diffuse Large B-Cell Lymphoma
Refractory Central Nervous System Lymphoma
Refractory Diffuse Large B-Cell Lymphoma
Recurrent Central Nervous System Lymphoma

Interventions: Biological: Nivolumab
Biological: Rituximab
Drug: Lenalidomide

First Posted Date: 2018-06-15

Last Posted Date: 2019-04-25

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 6

Registration Number: NCT03558750

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

Finding the Cause for Post-Transplant Diabetes Mellitus After Allogeneic Hematopoietic Cell Transplant

Recruiting

Conditions: Cancer
Diabetes Mellitus

Interventions: Drug: 2 OGTTs with and without GLP-1 analogue
Drug: Oral Glucose Tolerance Test (OGTT)
Drug: Hyperglycemic clamp procedure

First Posted Date: 2018-01-30

Last Posted Date: 2022-03-28

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 120

Registration Number: NCT03415139

Locations: 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States

Circulating Blood Profile to Predict Recurrence and Response to Systemic Therapy

Completed

Conditions: Melanoma

Interventions: Other: Blood draw (before surgery)
Other: Blood draw (every 3 months)
Other: Blood draw (at diagnosis)

First Posted Date: 2017-08-30

Last Posted Date: 2023-12-14

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 37

Registration Number: NCT03267381

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

Novel PET/CT Imaging Biomarkers of CB-839 in Combination With Panitumumab and Irinotecan in Patients With Metastatic and Refractory RAS Wildtype Colorectal Cancer

Phase 1

Completed

Conditions: Colorectal Cancer
Metastatic Colorectal Cancer
RAS Wild Type Colorectal Cancer
Refractory Colorectal Cancer

Interventions: Drug: Glutaminase Inhibitor CB-839
Biological: Panitumumab
Drug: Irinotecan Hydrochloride (phase I only)
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Device: Imaging with 11C-Glutamine PET/CT scans and 18F-FSPG PET/CT scans

First Posted Date: 2017-08-28

Last Posted Date: 2024-08-30

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 29

Registration Number: NCT03263429

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

Pevonedistat and Azacitidine in MDS or MDS/MPN Patients Who Fail Primary Therapy With DNA Methyl Transferase Inhibitors

Phase 2

Completed

Conditions: Myelodysplastic Syndromes
Myeloproliferative Neoplasm

Interventions: Drug: Azacitidine Subcutaneous Injection or Intravenous Infusion
Drug: Pevonedistat Infusion
Procedure: Bone Marrow Biopsy & Aspirate

First Posted Date: 2017-08-03

Last Posted Date: 2024-11-04

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 71

Registration Number: NCT03238248

Locations: 🇺🇸
University of Kansas Cancer Center, Westwood, Kansas, United States
🇺🇸
University of Rochester Medical Center, Rochester, New York, United States
🇺🇸
University of Miami Miller School of Medicine, Miami, Florida, United States

and more 2 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy